vTv Therapeutics Inc.
4170 Mendenhall Oaks Parkway
High Point
North Carolina
27265
United States
Tel: 336-841-0300 ext 100
Fax: 336-841-0310
Website: http://vtvtherapeutics.com/
131 articles with vTv Therapeutics Inc.
-
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
5/12/2022
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the progress of its clinical programs.
-
Noted Harvard researcher Doug Melton is heading to Vertex Pharmaceuticals to head up investigations into potential transformative treatments for type 1 diabetes.
-
vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update
3/30/2022
vTv Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2021, and provided an update on the progress of its clinical programs.
-
Six months into the job, Chief Executive Officer Deepa Prasad left vTv Therapeutics. Not long ago, the former CEO dramatically slashed its workforce to ensure funding for its lead diabetes asset.
-
vTv Therapeutics Announces CEO Transition
3/3/2022
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes, today announced that the Company has appointed Rich Nelson as Acting Chief Executive Officer.
-
In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.
-
Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.
-
vTv Therapeutics Shares Updated Corporate Presentation
1/13/2022
vTv Therapeutics Inc. is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population.
-
vTv Therapeutics said that the funds it saves through this process will allow it to focus on the Phase III development of TP399 and the company's future growth.
-
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
12/6/2021
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes, today announced the prioritization of its lead program TTP399 as it gears up for Phase 3 pivotal trials.
-
In October, Vertex Pharmaceuticals announced stunning results in a type 1 diabetes patient who had been dosed with the company’s experimental therapy.
-
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
11/9/2021
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the progress of its clinical programs.
-
vTv Therapeutics Announces Deepa Prasad as New President and CEO
10/20/2021
vTv Therapeutics Inc. today announced that Deepa Prasad will lead the company as President and Chief Executive Officer, effective immediately.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
10/12/2021
vTv Therapeutics Inc. today announced positive results of a mechanistic study of TTP399 in patients with type 1 diabetes (T1D).
-
The positive results from a mechanistic study of TTP399 in type 1 diabetes patients suggest that the drug can lower blood glucose without increasing the risk of DKA.
-
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
9/23/2021
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced results of a multiple ascending dose study evaluating HPP737, an orally administered phosphodiesterase type 4 (“PDE4”) inhibitor, in healthy adults.
-
vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update
8/4/2021
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progress of its clinical programs.
-
vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737
6/29/2021
vTv Therapeutics Inc. today announced that it will be presenting data from the clinical development of HPP737 as a treatment for psoriasis in a poster presentation at the 6th World Psoriasis & Psoriatic Arthritis Conference held virtually June 30 – July 3, 2021 in Stockholm, Sweden.
-
vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
6/22/2021
- vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv’s novel antagonist of RAGE (the receptor for advanced glycation endproducts).